1
Clinical Trials associated with Pentavalent Bioconjugate Candida Vaccine(LimmaTech Biologics AG)Candi5V01 A FTIH Phase I/II Randomized and Controlled Study to Test Safety, Immunogenicity and Preliminary Efficacy of a Pentavalent Bioconjugate Vaccine (Candi5V) Against Candida in Women With Recurrent Vulvovaginal Candidiasis.
In this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent vulvovaginal candidiasis.
100 Clinical Results associated with Pentavalent Bioconjugate Candida Vaccine(LimmaTech Biologics AG)
100 Translational Medicine associated with Pentavalent Bioconjugate Candida Vaccine(LimmaTech Biologics AG)
100 Patents (Medical) associated with Pentavalent Bioconjugate Candida Vaccine(LimmaTech Biologics AG)
100 Deals associated with Pentavalent Bioconjugate Candida Vaccine(LimmaTech Biologics AG)